{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:04:21Z","timestamp":1747181061229,"version":"3.40.5"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Gamma-aminobutyric acid A receptor, gamma 2 gene (GABRG2) encode the GABAA receptor which is responsible for fast neuronal inhibition. Polymorphisms in GABGR2 gene affect the clinical response of anti-epileptic drugs (AEDs). Therefore, we carried out an updated study to find the association GABRG2 gene polymorphisms with carbamazepine (CBZ) non-responsive therapy in the Pakhtun population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A clinical prospective cohort study was conducted in 79 CBZ treated patients upon consent after the approval of Khyber Medical University Advanced Study and Research Board. Blood sample were taken at optimal dose of CBZ at base line, third and sixth months of the treatment. Blood level of CBZ was measure through reverse phase high performance liquid chromatography (HPLC). Restriction fragment length polymorphisms techniques were used to genotype GABRG2 gene in these patients. CBZ responses were evaluated on three and six months of study by measuring the decrease in frequency of seizure per week.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The average maximum dose of CBZ was 455\u2005\u00b1\u2005133\u2009mg\/day at baseline, 479\u2005\u00b1\u2005142\u2009mg\/day at third month and 495\u2005\u00b1\u2005133\u2009mg\/day at sixth month of the treatment. CBZ level was found within therapeutic range (4\u201012\u2009mg\/L) without any significant (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u2005.5) variations among the CC, CT and TT genotypes of GABRG2 (C588T and C315T) gene. But the poor clinical response during CBZ treatment was linked (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05) with CT and TT genotypes of GABRG2 (C588T and C315T) gene in Pakhtun Population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>A poor response to CBZ was found in variant genotypes (CT and TT) of GABRG2 (C588T and C315T) gene in Pakhtun Population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000030948","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T15:05:43Z","timestamp":1665414343000},"page":"e30948","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The likelihood approach for potential role of \u201cGABRG2 (C588T, C315T) gene polymorphisms\u201d on the poor response to carbamazepine therapy in Pakhtun population of Pakistan"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7687-0227","authenticated-orcid":false,"given":"Shakir","family":"Ullah","sequence":"first","affiliation":[{"name":"Department of Pharmacology Institute of Basic Medical Science, Khyber Medical University, Peshawar, Khyber Pakhtunkhwa, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niaz","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Institute of Basic Medical Science, Khyber Medical University, Peshawar, Khyber Pakhtunkhwa, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajjad","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Institute of Basic Medical Science, Khyber Medical University, Peshawar, Khyber Pakhtunkhwa, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Wadood Ali","family":"Sha","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (Pharmacology), University of Malakand, Chakdara, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Neurology, Govt. Lady Reading Hospital Peshawar, Khyber Pakhtunkhwa, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feras","family":"Almarshad","sequence":"additional","affiliation":[{"name":"Dean College of Medicine, Shaqra, Riyad, Saudi Arabia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/mrdd.10035","article-title":"The epidemiology of the epilepsies in children.","volume":"8","author":"Cowan","year":"2002","journal-title":"Ment Retard Dev Disabil Res Rev"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1059-1311(97)80001-5","article-title":"Established antiepileptic drugs.","volume":"6","author":"Brodie","year":"1997","journal-title":"Seizure"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1046\/j.1528-1157.2001.04501.x","article-title":"Effectiveness of first antiepileptic drug.","volume":"42","author":"Kwan","year":"2001","journal-title":"Epilepsia"},{"key":"R4-20250504","first-page":"1685","article-title":"Genetic variations associated with pharmacoresistant epilepsy.","volume":"21","author":"C\u00e1rdenas-Rodr\u00edguez","year":"2020","journal-title":"Mol Med Rep"},{"key":"R5-20250504","first-page":"23","article-title":"La repercusi\u00f3n econ\u00f3mica de las enfermedades cr\u00f3nicas: El coste de la epilepsia infantil en el a\u00f1o 2000.","volume":"41","author":"Argumosa","year":"2001","journal-title":"Bol Pediatr"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2217\/pgs.11.141","article-title":"Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization.","volume":"13","author":"Hung","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R7-20250504","first-page":"117","article-title":"Genetic influences on the risk of epilepsy.","author":"Prasad","year":"2001","journal-title":"Pediatric Epilepsy"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1146\/annurev.ne.17.030194.003033","article-title":"GABAA receptor channels.","volume":"17","author":"Macdonald","year":"1994","journal-title":"Annu Rev Neurosci"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0896-6273(89)90257-2","article-title":"Two novel GABAA receptor subunits exist in distinct neuronal subpopulations.","volume":"3","author":"Shivers","year":"1989","journal-title":"Neuron"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"e34586","DOI":"10.1371\/journal.pone.0034586","article-title":"Complex control of GABA (A) receptor subunit mRNA expression: variation, covariation, and genetic regulation.","volume":"7","author":"Mulligan","year":"2012","journal-title":"PLoS One"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pediatrneurol.2006.09.011","article-title":"Association of GABRG2 polymorphisms with idiopathic generalized epilepsy.","volume":"36","author":"Chou","year":"2007","journal-title":"Pediatr Neurol"},{"issue":"5 Suppl 1","key":"R15-20250504","first-page":"S32","article-title":"Mechanisms of action of anticonvulsant agents.","volume":"55","author":"Mosh\u00e9","year":"1999","journal-title":"Neurology"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.nbd.2008.01.005","article-title":"Antiepileptic drug resistant rats differ from drug responsive rats in GABA A receptor subunit expression in a model of temporal lobe epilepsy.","volume":"31","author":"Bethmann","year":"2008","journal-title":"Neurobiol Dis"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.seizure.2010.02.009","article-title":"Association of alpha subunit of GABAA receptor subtype gene polymorphisms with epilepsy susceptibility and drug resistance in north Indian population.","volume":"19","author":"Kumari","year":"2010","journal-title":"Seizure"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/FPC.0000000000000000","article-title":"GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures.","volume":"23","author":"Balan","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.seizure.2018.06.004","article-title":"The genetic variant \u201cC588T\u201d of GABARG2 is linked to childhood idiopathic generalized epilepsy and resistance to antiepileptic drugs.","volume":"60","author":"El Ella","year":"2018","journal-title":"Seizure"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5114\/aoms.2016.63739","article-title":"GABRG2 C588T gene polymorphisms might be a predictive genetic marker of febrile seizures and generalized recurrent seizures: a case-control study in a Romanian pediatric population.","volume":"14","author":"Butil\u0103","year":"2018","journal-title":"Arch Med Sci"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejpn.2005.11.009","article-title":"The potential of pharmacogenetics in the treatment of epilepsy.","volume":"10","author":"Depondt","year":"2006","journal-title":"Eur J Paediatr Neurol"},{"key":"R23-20250504","first-page":"34","article-title":"Measuring the value of treatment to patients: patient-reported outcomes in drug development.","volume":"1","author":"Willke","year":"2008","journal-title":"Am Health Drug Benefits"},{"key":"R24-20250504","article-title":"Development and validation of an HPLC method for the determination of carbamazepine in human plasma.","volume":"10","author":"Ezzeldin","year":"2013","journal-title":"Life Sci J"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1528-1157.44.s.1.13.x","article-title":"Clues to the genetic influences of drug responsiveness in epilepsy.","volume":"44","author":"Ramachandran","year":"2003","journal-title":"Epilepsia"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1212\/01.wnl.0000255669.83468.dd","article-title":"GABAA receptor heterogeneity, function, and implications for epilepsy.","volume":"68","author":"Benarroch","year":"2007","journal-title":"Neurology"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/35088588","article-title":"Quality control in molecular genetic testing.","volume":"2","author":"Dequeker","year":"2001","journal-title":"Nat Rev Genet"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:40:15Z","timestamp":1746333615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":23,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030948","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,10,7]]}}}